Gianluca Castelnuovo, Isabel Fernandez, Benedikt L Amann
4 min
This editorial introduces a collection of 22 articles focused on the current state and future directions of Eye Movement Desensitization and Reprocessing (EMDR) therapy. Recognized by the World Health Organization as a first-choice treatment for Posttraumatic Stress Disorder (PTSD), EMDR is rooted in the Adaptive Information Processing (AIP) model, which suggests that psychopathology often stems from the incomplete processing of traumatic life experiences.
The research highlighted in this collection demonstrates a significant shift toward applying EMDR beyond its traditional use in PTSD. Recent studies explore its efficacy in treating various psychiatric and somatic comorbidities, including depression, substance use disorders, panic disorders, and even glioblastoma. Furthermore, the editorial notes the development of group-based EMDR protocols, which provide a scalable way to deliver trauma-focused care in resource-limited settings, such as mass disaster relief and refugee support.
A major focus of the editorial is the recent progress in understanding how EMDR works at a biological level. The authors highlight a landmark study using animal models that identified a specific neuroanatomical pathway: bilateral stimulation appears to increase activity in the superior colliculus and mediodorsal thalamus, which in turn reduces excitability in the amygdala. This provides a tangible neurobiological basis for the clinical observation that EMDR helps "rewrite" traumatic memory engrams.
As EMDR gains wider adoption among clinicians, the field is moving toward a more rigorous scientific foundation. By addressing both the clinical breadth of the therapy and its underlying neurobiological mechanisms, this research helps bridge the gap between psychotherapy practice and neuroscience. The editorial concludes that while the evidence base is strong, the future of the field depends on continued high-quality, methodology-driven research to refine its application across diverse patient populations.
EDITORIAL article Front. Psychol., 27 September 2019 | https://doi.org/10.3389/fpsyg.2019.02185
Sam: [quiet confidence, nodding] That's the central practical problem this addresses. For patients who can't tolerate traumatic material without a full stress response, exposure therapy is often contraindicated. A biological circuit breaker could lower the arousal threshold enough to make reconsolidation possible—it makes the patient accessible to the work of therapy again.
Alex: [pace picking up slightly, analytical edge] But this is animal-model evidence. How much of it transfers to humans, where the cognitive and emotional layers are so much messier? [[RP_SECTION:human-imaging-limitations|Human Imaging Limitations]]
Sam: [direct, acknowledging the weight of the point] That's the real limitation. Baek's study gives robust causal evidence in animals, but direct causal evidence from human neuroimaging during active EMDR sessions is still sparse. Motion artifacts during scanning and the sheer complexity of human trauma make it difficult to isolate these specific circuits in real time.
Alex: [beat of silence, then quieter and more reflective] So the mechanistic hypothesis holds up in the lab, but the human imaging data that would confirm it in a clinical setting isn't there yet.
Sam: [measured, honest] That's an accurate read of where the field stands. We've moved past dismissing the intervention as unfounded, but we haven't mapped the human neuroanatomical profile of these effects. The next phase needs methodologically rigorous studies that can actually track these changes in the human brain, not just infer them from animal work.
Alex: [deliberate, checking understanding, even pace] Does this open the door to something like precision psychotherapy—tailoring the stimulation protocol to a patient's specific neuroanatomical profile? [[RP_SECTION:future-of-precision-psychotherapy|Future of Precision Psychotherapy]]
Sam: [sitting back, broader perspective, calm and expansive] That's the long-term implication, if it holds. Identify which circuits are most involved in a given patient's trauma profile, and you could move away from one-size-fits-all protocols toward something more targeted—using neurobiological markers to guide the choice and intensity of the intervention.
Alex: [reflective, slower pace, voice settling] It sounds like the clinical efficacy that's been observed for decades is finally getting a neurobiological framework underneath it.
Sam: [warm, professional, quiet conviction] That's a fair way to put it. The field is moving from a period of clinical observation to one of mechanistic validation—which is where any evidence-based practice eventually needs to land. The foundation is there; confirming it in humans is the work still ahead.
Alex: [settling, closing tone] The figures, the imaging caveats, and the full case for how much of this generalizes—that's the kind of detail a deep dive into this paper would walk through properly. The paper itself has all of it either way.
Sam: [warm, brief] Thanks for listening.